RecallHawk

APTIOM (ESLICARBAZEPINE ACETATE)

SUMITOMO PHARMA AM

Summary

FDA approved APTIOM (ESLICARBAZEPINE ACETATE) by SUMITOMO PHARMA AM. NDA (New Drug) approval (Manufacturing (CMC)) on 2024-06-20. TABLET, ORAL.

Details

Source

Drug Approval

External ID

NDA022416-21

Action Date

2024-06-20

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

APTIOM (generic: ESLICARBAZEPINE ACETATE), TABLET, ORAL. Application: NDA022416

Context & Analysis

SUMITOMO PHARMA AM has 2 FDA actions in our database.

Frequently Asked Questions

How often does SUMITOMO PHARMA AM have FDA actions?

SUMITOMO PHARMA AM has 2 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA022416-21" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions